Abstract
Aims: The present study aimed to evaluate anti-diabetic properties of AgNPs/chitosan/ascorbic acid nanocomposites (Ag-NCs) in streptozotocin-induced diabetic rats. Main methods: Eighteen male Wistar albino rats were divided into three main groups (6 rats/group); control, diabetic and Ag-NCs groups. Control group: after a single dose of citrate buffer (0.1 mol/l, i.p), the rats orally received 1 ml distilled water daily for four weeks. The diabetic model was induced by a single dose of streptozotocin (60 mg/kg, i.p) for type 1diabetes. Diabetic groups were treated orally with and Ag-NCs (0.25mg/Kg body weight) daily for four weeks. Key findings: AgNPs/chitosan/ascorbic acid nanocomposite group showed a reduction in the concentrations of glucose, NO, MDA, creatinine, urea and uric acid. At the same time, it appeared a general increase in insulin, CAT, and SOD activities and GSH concentration. The histopathological investigation illustrated a clear improvement in renal architecture. Significance: The suggested mechanism of action for Ag-NCs in decreasing diabetic nephropathy includes two pathways; the hypoglycemic activity and the antioxidant role of Ag-NCs
Highlights
Diabetes Mellitus (DM) is epidemic disorder of endocrine system which characterized by glucose intolerance due to high blood glucose levels and disturbed metabolism of carbohydrates, proteins, and lipids
Diabetes mellitus is classified into type 1 diabetes which characterized by insufficient production of insulin hormone due to an autoimmune damage of the pancreatic β cells through T-cell mediated insulitis in addition to the response of a humoral (B cell) [3] and type 2 diabetes includes insulin resistance or impaired insulin secretion
One of the most destructive complications of type 1 diabetes mellitus (T1DM) is diabetic nephropathy (DN) that often results in end-stage renal disease (ESRD)
Summary
Diabetes Mellitus (DM) is epidemic disorder of endocrine system which characterized by glucose intolerance due to high blood glucose levels and disturbed metabolism of carbohydrates, proteins, and lipids. The global diabetes prevalence in 2019 is projected to be 9.3% (463 million people), increasing to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The number of people living worldwide with diabetes is estimated to increase by 25% in 2030 and will be doubled to 51% in 2045 [2]. A new term of diabetes would be described as type 3 diabetes which used for insulin resistance in brain [4]. One of the most destructive complications of type 1 diabetes mellitus (T1DM) is diabetic nephropathy (DN) that often results in end-stage renal disease (ESRD)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call